MID-VOLUME · HOSP-MID
insulin degludec Side Effects
insulin degludec (also sold as Tresiba) sits MID-VOLUME #226 of 524 by FAERS report count. Lead signal: HOSP-MID - 28.8% mention hospitalization (6,329 reports). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 22,011
- FAERS reports
FDA Adverse Event Reporting System extract for insulin degludec. Stamp set WATCHLIST · DEATH-HEAVY · HOSP-MID. How figures are compiled.
insulin degludec: 28.8% mention hospitalization (6,329 reports). Death stamp DEATH-HEAVY; volume band MID-VOLUME #226 of 524 by FAERS report count.
Mid-book FAERS page for insulin degludec (Tresiba) (22,011 reports). Signature HOSP-MID. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2011–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
BLOOD GLUCOSE INCREASED leads 3,617 of 22,011 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (4,924 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (1,194 reports, 5.4%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 447 |
| SEPSIS | 265 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 253 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 248 |
| VOMITING | 248 |
| ASCITES | 245 |
| NAUSEA | 243 |
| HYPONATRAEMIA | 241 |
| CONSTIPATION | 237 |
| CARDIOGENIC SHOCK | 236 |
| ABDOMINAL PAIN | 235 |
| APPENDICITIS | 235 |
| STRESS | 235 |
| APPENDICOLITH | 234 |
| ABDOMINAL DISTENSION | 230 |
| VENTRICULAR FIBRILLATION | 193 |
| CONDITION AGGRAVATED | 159 |
| SOMNOLENCE | 149 |
| BLOOD PHOSPHORUS INCREASED | 143 |
Reactions in Hospitalization Reports
Hospitalization mid-share (6,329, 28.8%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| BLOOD GLUCOSE INCREASED | 512 |
| NAUSEA | 453 |
| VOMITING | 423 |
| HYPOGLYCAEMIA | 409 |
| FALL | 336 |
| DIABETIC KETOACIDOSIS | 334 |
| DYSPNOEA | 316 |
| PNEUMONIA | 302 |
| DIARRHOEA | 286 |
| ACUTE KIDNEY INJURY | 284 |
| HOSPITALISATION | 250 |
| FATIGUE | 240 |
| ABDOMINAL PAIN | 234 |
| CONSTIPATION | 233 |
| CONDITION AGGRAVATED | 232 |
| SEPSIS | 224 |
| BLOOD GLUCOSE DECREASED | 214 |
| ASTHENIA | 195 |
How to read insulin degludec FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-MID)
FAERS holds 22,011 voluntary reports linked to insulin degludec (Tresiba), 2011-2025. Death is listed on 1,194 (5.4%). Hospitalization appears on 6,329 (28.8%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-HEAVY · HOSP-MID as signal-detection rates next to 28.8% mention hospitalization (6,329 reports).
Read with insulin degludec
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 22,227 FAERS cases (Δ 216 heavier vs insulin degludec); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 22,556 FAERS cases (Δ 545 heavier vs insulin degludec); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 21,352 FAERS cases (Δ 659 lighter vs insulin degludec); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 22,750 FAERS cases (Δ 739 heavier vs insulin degludec); DEATH-HEAVY · HOSP-MID · FEMALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 56.7 pp vs insulin degludec's DEATH-HEAVY): CASELOAD · HOSP-MID.
insulin degludec stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.